-
Mashup Score: 2Teva CEO on Drug Pricing, Generics, Supply Shortages - 11 day(s) ago
Teva Pharmaceuticals CEO Richard Francis reflects on company performance in 2024, drug pricing, getting more drugs to market and supply shortages of the drug Adderall. He speaks to “Bloomberg Open Interest” from the JPMorgan Healthcare Conference. (Source: Bloomberg)
Source: www.bloomberg.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 16Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease - 1 month(s) ago
Teva hosting investor call today at 8:00 a.m. ET (U.S.) Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibody Sanofi and Teva plan to initiate Phase 3 development in IBD, pending regulatory discussions PARSIPPANY, N.J. and PARIS, Dec. 17, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva
Source: www.tevapharm.comCategories: General Medicine News, PayerTweet-
#NEWS: Teva and @Sanofi announce positive topline results for our anti-TL1A program for patients with #IBD. Read more here: https://t.co/dqvjiFygIS $Teva https://t.co/RJwVLFBca5
-
-
Mashup Score: 5
For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms, compared to Q3 2023. AUSTEDO ® – shows continued growth, U.S. revenues of $435 million in Q3 2024, an increase of 28% compared to Q3 2023; reaffirming 2024 revenue outlook of ~$1.6 billion. AJOVY ® – global revenues of $137 million in Q3 2024, an increase of 21% in local currency terms compared to Q3 2023. UZEDY ® is gaining momentum – U.S. revenues of $35 million in Q3 2024; raising 2024 revenues outlook from ~$80 million to ~$100 million. Early and late-stage innovative pipeline continues to progress, with duvakitug (Anti-TL1A) top-line results expected in Q4 2024, and TEV-‘749 (olanzapine LAI) achieving phase III target injections without PDSS. Generics business grows across all regions – increased by 30% in the U.S., 8% in Europe and 13% in International Markets, in local currency terms compared
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q3 2024 business results. https://t.co/P8rEXLxooh Forward-looking statements are subject to the cautionary note included in our Q3 2024 press release. #QuarterlyResults #Earnings $Teva https://t.co/kdh7MEPSBd
-
-
Mashup Score: 4
For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms, compared to Q3 2023. AUSTEDO ® – shows continued growth, U.S. revenues of $435 million in Q3 2024, an increase of 28% compared to Q3 2023; reaffirming 2024 revenue outlook of ~$1.6 billion. AJOVY ® – global revenues of $137 million in Q3 2024, an increase of 21% in local currency terms compared to Q3 2023. UZEDY ® is gaining momentum – U.S. revenues of $35 million in Q3 2024; raising 2024 revenues outlook from ~$80 million to ~$100 million. Early and late-stage innovative pipeline continues to progress, with duvakitug (Anti-TL1A) top-line results expected in Q4 2024, and TEV-‘749 (olanzapine LAI) achieving phase III target injections without PDSS. Generics business grows across all regions – increased by 30% in the U.S., 8% in Europe and 13% in International Markets, in local currency terms compared
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
As we continue to deliver on our #PivotToGrowth strategy, we're sharing today Teva’s Q3 2024 business results. https://t.co/P8rEXLxooh Forward-looking statements are subject to the cautionary note included in our Q3 2024 press release. #QuarterlyResults #Earnings $Teva https://t.co/kdh7MEPSBd
-
-
Mashup Score: 7Expanding access to mental health care - 3 month(s) ago
Community Routes: Access to Mental Health Care — a partnership between Teva, Direct Relief and the National Association of Free and Charitable Clinics (NAFC) — is a unique access program that is helping to advance health equity and quality care for underserved populations across the U.S. Teva is providing commonly used medicines that treat depression and anxiety over $17 million as well as $2 million in grant funding over two years to support innovative behavioral health services through local free and
Source: www.tevausa.comCategories: General Medicine News, PayerTweet-
Big news! Teva, in partnership with @NAFClinics and @DirectRelief, is a winner of the @USCCFoundation Citizens Award. Read more about how our program is helping bring medicines to patients wherever they are. https://t.co/9otAJaNlzg #BusinessSolves #TevaUSA
-
-
Mashup Score: 4
Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection in April 2024 SELARSDI’s U.S. launch for all indications is expected in Q1 2025 REYKJAVIK, Iceland PARSIPPANY, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) – Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion. This approval paves the way for SELARSDI to further align its label with the indications of the reference product Stelara ® (ustekinumab) in the U.S. at launch, which is expected
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
#NEWS: The U.S. FDA approves an expanded label for one of our partnered #biosimilar products, extending to use in treatment of adults with Crohn’s disease and ulcerative colitis. Read more here: https://t.co/N60EM1e59S https://t.co/jvBgpFXDVQ
-
-
Mashup Score: 4Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA - 4 month(s) ago
Prolia ® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal women TVB-009P, Teva’s proposed biosimilar to Prolia, showed Phase 3 clinical results in osteoporosis and is part of Teva’s robust biosimilar portfolio – 7 approved biosimilars and 16 in the pipeline – across critical therapeutic areas such as oncology, immunology and respiratory medicine Anticipated decision by both agencies is expected in 2H 2025 TEL AVIV, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia ® (denosumab). 1 Both applications, a Biologics License Application (BLA) in the U.S., seeking interchangeability, and a Marketing Authorization Application (MAA) in the
Source: ir.tevapharm.comCategories: General Medicine News, PayerTweet-
#NEWS: The U.S. Food and Drug Administration has accepted and the European Medicines Agency has validated applications for one of our biosimilar candidates. Read more here: https://t.co/Hjq82Ytm6Y https://t.co/6Und85woRS
-
-
Mashup Score: 42024 Citizens Awards Finalists - 4 month(s) ago
This year, we highlight 30 companies that have shown outstanding leadership in driving solutions to the world’s most pressing challenges.
Source: www.uschamberfoundation.orgCategories: General Medicine News, PayerTweet-
We are honored to be a @USChamber Citizens Award Finalist for Best Health & Wellness Program for our Community Routes program. With @DirectRelief & @NAFClinics, we’re providing behavioral health services & medicines for those who need them. https://t.co/hay0eVcXST #BusinessSolves https://t.co/bFYveVoic8
-
-
Mashup Score: 3Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S. - 4 month(s) ago
This first-to-market launch showcases Teva’s proven strengths in complex generic formulations and enhances Teva’s strategic goal of sustaining a generic powerhouse. O ctreotide acetate for injectable suspension is indicated to treat a cromegaly and severe diarrhea for carcinoid syndrome. PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and only generic version of
Source: www.tevausa.comCategories: General Medicine News, PayerTweet-
#NEWS: Today we are announcing the launch of the first and only generic version of octreotide acetate for injectable suspension in the U.S. Learn more about this treatment and our commitment to ensuring patient access to quality generics: https://t.co/tSGfEJkS3A https://t.co/KtoqnfbwtD
-
-
Mashup Score: 7LinkedIn - 6 month(s) ago
This link will take you to a page that’s not on LinkedIn
Source: lnkd.inCategories: General Medicine News, PayerTweet-
Yesterday Teva CEO Richard Francis talked with @moneymoverscnbc about our strong momentum, Q2 business performance and the progress on our #PivotToGrowth strategy. Watch the full interview here: https://t.co/ennQTtxsne View highlights below: https://t.co/cUAGpKmJXc
-
Speaking with Bloomberg at the J.P. Morgan Healthcare Conference 2025, Teva President and CEO Richard Francis reflected on the company’s exceptional performance in the first three quarters of 2024. Watch the full interview here: https://t.co/K9xVd1AhWe #TevaUSA #JPM25 https://t.co/pSd2vHaxAE